Form D · Pharmaceuticals
BioQ Pharma Inc
San Francisco, CA · CIK 0001278320
Offering snapshot reported Jan 10, 2020 · SEC filing
- Reported sold
- $4.64M Offering amount: $18.8M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 30, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2020 | Initial | $4,637,500 | No comparison | 15 | SEC filing |
| Nov 5, 2018 | Amendment | $36,405,000 | $18,110,000vs Aug 7, 2017 | 52 | SEC filing |
| Aug 10, 2017 | Initial | $6,250,000 | No comparison | 2 | SEC filing |
| Aug 7, 2017 | Amendment | $18,295,000 | $6,085,000vs Dec 15, 2015 | 50 | SEC filing |
| Oct 20, 2016 | Initial | $15,040,000 | No comparison | 1 | SEC filing |
| Dec 15, 2015 | Initial | $12,210,000 | No comparison | 16 | SEC filing |
| Nov 10, 2014 | Initial | $13,737,000 | No comparison | 2 | SEC filing |
| Apr 19, 2013 | Initial | $8,073,135 | No comparison | 51 | SEC filing |
| Nov 23, 2010 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Apr 28, 2006 | Paper | Not reported | No comparison | Not reported |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-357701
Source: Form D, filed Jan 10, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark J. Ehlert | Director |
| Norvall William Jasper, Jr. | Director |
| Llew Keltner | Director |
| Marshall S. Kriesel | Director |
| Joshua W. Kriesel | Director, Executive |
| John W. Morgan | Director |
| Richard Nesbit | Director |
| Ron Pauli | Executive |
| Christopher Portman | Director |
| Daniel Tasse | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1325 Howard Street
San Francisco, CA, 94103
San Francisco, CA, 94103